Mannkind Has Launched INHALE-3 Study In Type 1 Diabetes Adult Patients Comparing A1c And Mealtime Control When Switching From Injectable Insulin Or Pumps To Inhaled Insulin (Afrezza (Insulin Human) Inhalation Powder)
Portfolio Pulse from Benzinga Newsdesk
MannKind has initiated the INHALE-3 study in adult patients with Type 1 diabetes, comparing A1c and mealtime control when switching from injectable insulin or pumps to inhaled insulin (Afrezza).
June 22, 2023 | 10:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MannKind has launched the INHALE-3 study for Type 1 diabetes patients, potentially increasing the adoption of its inhaled insulin product, Afrezza.
The launch of the INHALE-3 study indicates that MannKind is actively working to demonstrate the efficacy of its inhaled insulin product, Afrezza, in Type 1 diabetes patients. If the study yields positive results, it could lead to increased adoption of Afrezza, positively impacting MannKind's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100